1.Effects of intensive versus mild lipid lowering by statins in patients with ischemic congestive heart failure: Korean Pitavastatin Heart Failure (SAPHIRE) study.
Hae Young LEE ; Hyun Jai CHO ; Hee Yul KIM ; Hee Kyung JEON ; Joon Han SHIN ; Suk Min KANG ; Sang Hong BAEK
The Korean Journal of Internal Medicine 2014;29(6):754-763
BACKGROUND/AIMS: This study was designed to evaluate the dose-effect relationship of statins in patients with ischemic congestive heart failure (CHF), since the role of statins in CHF remains unclear. METHODS: The South koreAn Pitavastatin Heart FaIluRE (SAPHIRE) study was designed to randomize patients with ischemic CHF into daily treatments of 10 mg pravastatin or 4 mg pitavastatin. RESULTS: The low density lipoprotein cholesterol level decreased by 30% in the pitavastatin group compared with 12% in the pravastatin (p < 0.05) group. Left ventricular systolic dimensions decreased significantly by 9% in the pitavastatin group and by 5% in the pravastatin group. Left ventricular ejection fraction (EF) improved significantly from 37% to 42% in the pitavastatin group and from 35% to 39% in the pravastatin group. Although the extent of the EF change was greater in the pitavastatin group (16% vs. 11%) than that in the pravastatin group, no significant difference was observed between the groups (p = 0.386). Exercise capacity, evaluated by the 6-min walking test, improved significantly in the pravastatin group (p < 0.001), but no change was observed in the pitavastatin group (p = 0.371). CONCLUSIONS: Very low dose/low potency pravastatin and high dose/high potency pitavastatin had a beneficial effect on cardiac reverse remodeling and improved systolic function in patients with ischemic CHF. However, only pravastatin significantly improved exercise capacity. These findings suggest that lowering cholesterol too much may not be beneficial for patients with CHF.
Aged
;
Biological Markers/blood
;
Cholesterol, LDL/*blood
;
Down-Regulation
;
Dyslipidemias/blood/diagnosis/*drug therapy/epidemiology
;
Exercise Tolerance/drug effects
;
Female
;
Heart Failure/diagnosis/*drug therapy/epidemiology/physiopathology
;
Humans
;
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & dosage/adverse effects
;
Male
;
Middle Aged
;
Myocardial Ischemia/diagnosis/*drug therapy/epidemiology/physiopathology
;
Pravastatin/*administration & dosage/adverse effects
;
Prospective Studies
;
Quinolines/*administration & dosage/adverse effects
;
Recovery of Function
;
Republic of Korea
;
Stroke Volume/drug effects
;
Time Factors
;
Treatment Outcome
;
Ventricular Function, Left/drug effects
;
Ventricular Remodeling/drug effects
2.Prognostic value of hyponatremia in heart failure patients: an analysis of the Clinical Characteristics and Outcomes in the Relation with Serum Sodium Level in Asian Patients Hospitalized for Heart Failure (COAST) study.
Byung Su YOO ; Jin Joo PARK ; Dong Ju CHOI ; Seok Min KANG ; Juey Jen HWANG ; Shing Jong LIN ; Ming Shien WEN ; Jian ZHANG ; Junbo GE
The Korean Journal of Internal Medicine 2015;30(4):460-470
BACKGROUND/AIMS: Hyponatremia is a well-known risk factor for poor outcomes in Western studies of heart failure (HF) patients. We evaluated the predictive value of hyponatremia in hospitalized Asian HF patients. METHODS: The Clinical Characteristics and Outcomes in the Relation with Serum Sodium Level in Asian Patients Hospitalized for Heart Failure (the COAST) study enrolled hospitalized patients with systolic HF (ejection fraction < 45%) at eight centers in South Korea, Taiwan, and China. The relationship between admission sodium level and clinical outcomes was analyzed in 1,470 patients. RESULTS: The mean admission sodium level was 138 +/- 4.7 mmol/L, and 247 patients (16.8%) had hyponatremia defined as Na+ < 135 mmol/L. The 12-month mortality was higher in hyponatremic patients (27.9% vs. 14.6%, p < 0.001), and hyponatremia was an independent predictor of 12-month mortality (hazard ratio, 1.72; 95% confidence interval, 1.12 to 2.65). During hospital admission, 57% of hyponatremic patients showed improvement without improvement in their clinical outcomes (p = 0.620). The proportion of patients with optimal medical treatment was only 26.5% and 44.2% at admission and discharge, respectively, defined as the combined use of angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker and beta-blocker. Underuse of optimal medical treatment was more pronounced in hyponatremic patients. CONCLUSIONS: In hospitalized Asian HF patients, hyponatremia at admission is common and is an independent predictor of poor clinical outcome. Furthermore, hyponatremic patients receive less optimal medical treatment than their counterparts.
Aged
;
Aged, 80 and over
;
Asia/epidemiology
;
*Asian Continental Ancestry Group
;
Biomarkers/blood
;
Cardiovascular Agents/therapeutic use
;
Disease-Free Survival
;
Female
;
Guideline Adherence
;
Healthcare Disparities
;
Heart Failure/*diagnosis/drug therapy/ethnology/mortality/physiopathology
;
*Hospitalization
;
Humans
;
Hyponatremia/blood/*diagnosis/drug therapy/ethnology/mortality
;
Male
;
Middle Aged
;
Practice Guidelines as Topic
;
Predictive Value of Tests
;
Proportional Hazards Models
;
Risk Factors
;
Sodium/*blood
;
Stroke Volume
;
Time Factors
;
Treatment Outcome